Novo's first EU Tresiba launches in UK and Denmark, but no relief from US anguish
This article was originally published in Scrip
Novo Nordisk’s launch of its diabetes treatment Tresiba (insulin degludec) in the UK and Denmark has been heralded by diabetics medics as proving greater compliance and safety, but even unbridled success in these markets would only go so far to temper the blow of the US FDA’s rejection of the product last month.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.